

Eventi avversi e tollerabilità del trattamento immunoterapico nei pazienti con melanoma

Bibliografia

1. Wolchock, J. D. *et al.* Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. *Lancet Oncol.* **11**, 155–164 (2010).
2. Hodi, F. S. *et al.* Improved survival with ipilimumab in patients with metastatic melanoma. *N. Engl. J. Med.* **363**, 711–723 (2010).
3. Weber, J. S. *et al.* Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. *Cancer* **119**, 1675–1682 (2013).
5. Gupta, A. *et al.* Systematic review: colitis associated with anti-CTLA-4 therapy. *Aliment. Pharmacol. Ther.* **42**, 406–417 (2015).
4. Weber, J. S. *et al.* Management of immune-related adverse events and kinetics of response with ipilimumab. *J. Clin. Oncol.* **30**, 2691–2697 (2012).
6. Marthey, L. *et al.* Ipilimumab colitis: a GETAID multicentric study [poster P202]. *J. Crohns Colitis* **8**, S146 (2014).
7. Dignass, A. *et al.* Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. *J. Crohns Colitis* **6**, 991–1030 (2012).
8. Beck, K. E. *et al.* Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. *J. Clin. Oncol.* **24**, 2283–2289 (2006).
9. Berman, D. *et al.* Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. *Cancer Immun.* **10**, 11 (2010).
10. Lacouture, M. E. *et al.* Ipilimumab in patients with cancer and the management of dermatologic adverse events. *J. Am. Acad. Dermatol.* **71**, 161–169 (2014).
11. Voskens, C. J. *et al.* The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. *PLoS ONE* **8**, e53745 (2013).
12. Delyon, J. *et al.* Hemophilia A induced by ipilimumab. *N. Engl. J. Med.* **365**, 1747–1748 (2011).
13. Robinson, M. R. *et al.* Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis. *J. Immunother.* **27**, 478–479 (2004).
14. Weber, J. S. *et al.* Phase I/II study of ipilimumab for patients with metastatic melanoma. *J. Clin. Oncol.* **26**, 5950–5956 (2008).
15. Topalian, S. L. *et al.* Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. *N. Engl. J. Med.* **366**, 2443–2454 (2012).
16. Patnaik, A. *et al.* Phase I study of MK-3475 (anti-PD-1 monoclonal antibody) in patients with advanced solid tumors [abstract]. *J. Clin. Oncol.* **33** (Suppl.), a2512 (2012).
17. Brahmer, J. R. *et al.* Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic

- correlates. *J. Clin. Oncol.* **28**, 3167–3175 (2010).
18. Hamid, O. *et al.* Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. *N. Engl. J. Med.* **369**, 134–144 (2013).
19. Robert, C. *et al.* Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. *Lancet* **384**, 1109–1117 (2014).
20. Larkin, J. *et al.* Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. *N. Engl. J. Med.* **373**, 23–34 (2015).
21. Orlov, S. *et al.* Induction of painless thyroiditis in patients receiving programmed death 1 receptor immunotherapy for metastatic malignancies. *J. Clin. Endocrinol. Metab.* **100**, 1738–1741 (2015).
22. Weber, J. S. *et al.* Safety profile of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL): a pooled analysis [abstract]. *J. Clin. Oncol.* **33** (Suppl.), a9018 (2015).
23. Wolchok, J. D. *et al.* Nivolumab plus ipilimumab in advanced melanoma. *N. Engl. J. Med.* **369**, 122–133 (2013).
24. Sznol, M *et al.* Pooled analysis profile of nivolumab and ipilimumab combination therapy in patients with advanced melanoma.]. *J. Clin. Oncol.* **35**:3815-3822
25. Lichtiger, S. *et al.* Cyclosporine in severe ulcerative colitis refractory to steroid therapy. *N. Engl. J. Med.* **330**, 1841–1845 (1994).
26. Pages, C. *et al.* Ipilimumab-induced acute severe colitis treated by infliximab. *Melanoma Res.* **23**, 227–230 (2013).
27. Minor, D. R. *et al.* Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis. *Cancer Biother. Radiopharm.* **24**, 321–325 (2009).
28. Merrill, S. P. *et al.* Early administration of infliximab for severe ipilimumab-related diarrhea in a critically ill patient. *Ann. Pharmacother.* **48**, 806–810 (2014).
29. Douglas, B. J. *et al.* Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders [abstract]. *J. Clin. Oncol.* **33** (Suppl.), a9019 (2015).